

# Buscopan™ Compositum

## Presentation

Solution for injection. Each ml contains 4 mg butylscopolamine bromide and 500 mg metamizole (INN) as active ingredients plus 5 mg phenol (Ph.Eur) as preservative.

## Uses

**Actions:** Butylscopolamine bromide is a spasmolytic and analgesic agent with particular activity on the smooth muscle of the digestive and urinary systems. Metamizole is a non-steroidal anti-inflammatory drug of the pyrazolone group and also has analgesic and anti-pyretic properties.

## Indications

- As an aid in the control of pain associated with simple equine colic and as a diagnostic aid in more severe equine colics.
- For the control of diarrhoea in cattle, horses and dogs particularly when pain or abdominal discomfort is present.
- For the control of pain associated with urinary obstruction in horses and dogs.

## Dosage and administration

Use aseptic techniques

Horses	5 ml per 100 kg bodyweight by intravenous route only
Adult Cattle	5 ml per 100 kg bodyweight by intravenous or intramuscular injection
Calves	5 ml per 50 kg bodyweight by intravenous or intramuscular injection
Dogs	0.1 ml per kg bodyweight by intravenous or intramuscular injection

## WITHDRAWAL PERIOD START

### Withdrawal Period Information - PLEASE DO NOT REMOVE

<i>Include in WP Book (yes/no)</i>	<i>Changed since last WP Book (yes/no)</i>	<i>Cattle Milk</i>	<i>Cattle Meat</i>	<i>Sheep Meat</i>	<i>Pig Meat</i>	<i>Poultry Meat</i>	<i>Poultry Eggs</i>	<i>Fish Meat</i>	<i>Notes</i>
Yes	No	-	9 days iv 28 days im	-	-	-	-	-	Horses 9 days. Do not use in milking cows.

## WITHDRAWAL PERIOD END

## Contra-indications, warnings, etc

Due to a risk of local reactions, do not use the intramuscular route in horses.

Studies in laboratory animals (rabbit, rat) have not produced any evidence of a teratogenic effect. No information on use during pregnancy in the target species is available and therefore should not be used.

### *Withdrawal periods for meat*

Horses - 9 days

Cattle - 9 days after intravenous injection, 28 days after intramuscular injection.

Do not use in cows producing milk for human consumption.

The effects of metamizole and/or butylscopolamine bromide may be potentiated by concurrent use of other anticholinergic or analgesic drugs.

The acute toxicity of both compounds is very low. In studies with rats, the symptoms were non-specific and included ataxia, mydriasis, tachycardia, prostration, convulsions, coma and respiratory signs.

Symptomatic treatment should be initiated in case of overdosage.

Take care to avoid selfinjection. In a very small number of people, metamizole can cause reversible, but potentially serious agranulocytosis and other reactions such as skin allergy. Avoid use of the product if you are known to be sensitive to pyrazolones, or are sensitive to aspirin. Wash any splashes from the skin. If accidental selfinjection occurs, seek medical advice and show the Doctor the product packaging.

Unused product or waste material should be disposed of in accordance with current practice for pharmaceutical waste under national waste disposal regulations.

### **Pharmaceutical precautions**

Do not store above 25°C. Protect from light.

Following withdrawal of the first dose use the product within 28 days after which discard unused material.

Keep out of reach of children.

For animal treatment only.

### **Legal category**

POM

### **Package quantities**

100 ml multidose glass injection bottles.

### **Further information**

In horses, a slight transient increase in heart rate may be observed due to the parasympatholytic activity of butylscopolamine bromide.

### **Marketing authorisation number**

VM00015/4065